Actionable gene
|
Histotype
|
Drug response
|
Differences in TCGA protein profiles
|
---|
BRAF
|
SKCM*
|
Y
|
Y
|
ERBB2
|
BRCA*
|
Y
|
Y
|
STAD*
|
Y
|
Y
|
LUAD
|
Y
|
Y
|
PAAD
|
N
|
N
|
EGFR
|
LUAD*
|
Y
|
Y
|
FGFR1
|
LUSC*
|
Y
|
Y
|
COAD
|
N
|
N
|
UCEC
|
N
|
Y
|
SKCM*
|
Y
|
Y
|
KRAS
|
LUAD
|
Y
|
Y
|
UCEC
|
N
|
Y
|
COAD*
|
N
|
N
|
STAD
|
N
|
N
|
LUAD
|
Y
|
Y
|
MET
|
GBM
|
N
|
Y
|
SKCM
|
N
|
N
|
STAD
|
Y
|
N
|
BRCA
|
N
|
Y
|
KIRP
|
Y
|
Y
|
KIRC*
|
N
|
N
|
OV
|
N
|
Y
|
LUAD
|
Y
|
Y
|
PIK3CA
|
BLCA
|
Y
|
N
|
HNSC
|
N
|
N
|
STAD
|
N
|
Y
|
- *Histotypes where the gene is clinically established as actionable are marked. Fisher’s exact test shows there is a significant relation between protein discriminability and drug response (p = 0.0484)
- bold: Response to targeted drugs and protein profile differences were consistently both present (Y) or both absent (N)